Puma Biotechnology Reports Third Quarter 2026 Financial Results

On November 5, 2026 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported financial results for the third quarter ended September 30, 2026. Unless otherwise stated, all comparisons are for the third quarter of 2026 compared to the third quarter of 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Product revenue, net consists entirely of revenue from sales of NERLYNX, Puma’s first commercial product. Product revenue, net in the third quarter of 2026 was $54.1 million, compared to product revenue, net of $51.9 million in the third quarter of 2025. Product revenue, net in the first nine months of 2026 was $149.6 million, compared to $144.2 million in the first nine months of 2025.

Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $6.0 million, or $0.12 per basic share and $0.11 per diluted share, for the third quarter of 2026, compared to net income of $8.8 million, or $0.18 per basic share and $0.17 per diluted share, for the third quarter of 2025.

Net income for the first nine months of 2026 was $10.4 million, or $0.20 per basic and diluted share, compared to net income of $17.7 million, or $0.35 per basic and diluted share, for the first nine months of 2025.

Non-GAAP adjusted net income was $8.0 million, or $0.15 per basic and diluted share, for the third quarter of 2026, compared to non-GAAP adjusted net income of $10.5 million, or $0.21 per basic and diluted share, for the third quarter of 2025. Non-GAAP adjusted net income for the first nine months of 2026 was $16.3 million, or $0.32 per basic share and $0.31 per diluted share, compared to non-GAAP adjusted net income of $23.0 million, or $0.46 per basic and diluted share, for the first nine months of 2025. Non-GAAP adjusted net income excludes stock-based compensation expense. For a reconciliation of GAAP net income to non-GAAP adjusted net income and GAAP net income per share to non-GAAP adjusted net income per share, please see the financial tables at the end of this news release.

Net cash provided by operating activities for the third quarter of 2026 was $14.6 million, compared to $9.7 million in the third quarter of 2025. Net cash provided by operating activities for the first nine months of 2026 was $31.6 million, compared to net cash provided by operating activities of $27.4 million in the first nine months of 2025. At September 30, 2026, Puma had cash, cash equivalents and marketable securities of $108.5 million, compared to cash, cash equivalents and marketable securities of $97.5 million at December 31, 2025.

"Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and 340B sales, as well as a delay in sales to Puma’s ex-U.S. commercial partners that shifted from the third quarter to the fourth quarter," said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. "We continue to anticipate increased year-over-year demand for NERLYNX, while we continue to advance alisertib across our ALISCA clinical development programs. During the quarter, we initiated ALISCA-Lung2, a Phase II trial evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer, further expanding our clinical development program in this area, while we are continuing to enroll the ALISCA-Breast1 and ALISCA-Lung1 trials."

Mr. Auerbach added, "We anticipate the following key milestones over the next 12 months: (i) presentation of updated data from ALISCA-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (San Antonio Breast Cancer Symposium, December 2026); (ii) initiation of discussions with global regulatory agencies regarding the Phase III trial design for alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (H1 2027); (iii) continued

enrollment in ALISCA-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer to obtain more data in biomarker focused populations (H2 2026); (iv) continued enrollment of ALISCA-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer and ALISCA-Lung2, a Phase II trial evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer (Q4 2026); and (v) presentation of updated data from ALISCA-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (2027)."

Revenue

Total revenue consists of product revenue, net from sales of NERLYNX, Puma’s first commercial product, and royalty revenue. For the third quarter ended September 30, 2026, total revenue was $55.1 million, of which $54.1 million was net product revenue and $1.0 million was royalty revenue. This compares to total revenue for the third quarter of 2025 of $54.5 million, of which $51.9 million was net product revenue and $2.6 million was royalty revenue. For the first nine months of 2026, total revenue was $156.4 million, of which $149.6 million was net product revenue and $6.8 million was royalty revenue. This compares to total revenue for the first nine months of 2025 of $152.9 million, of which $144.2 million was net product revenue and $8.7 million was royalty revenue. The third quarter and first nine months of 2026 included a $2.1 million reduction to royalty revenue as a change in accounting estimate, reflecting the receipt of new third-party market data confirming that the market share of generic versions of NERLYNX in China reached a specified threshold during the period.

Operating Costs and Expenses

Total operating costs and expenses were $49.8 million for the third quarter of 2026 , compared to $44.9 million for the third quarter of 2025. Operating costs and expenses in the first nine months of 2026 were $147.4 million, compared to $132.7 million in the first nine months of 2025. The year-to-date increases were primarily attributable to increases in R&D expenses and cost of sales.

Cost of Sales

Cost of sales was $15.2 million for the third quarter of 2026, compared to $12.2 million for the third quarter of 2025. Cost of sales was $38.1 million for the first nine months of 2026, compared to $35.0 million for the first nine months of 2025. The increases in cost of sales for the third quarter and first nine months of 2026 were due primarily to higher product sales to an international partner.

Selling, General and Administrative Expenses

Selling, general and administrative (SG&A) expenses were $16.3 million for the third quarter of 2026, compared to $16.8 million for the third quarter of 2025. SG&A expenses for the first nine months of 2026 were $52.3 million, compared to $52.5 million for the first nine months of 2025, and were virtually unchanged year over year.

Research and Development Expenses

Research and development (R&D) expenses were $18.3 million for the third quarter of 2026, compared to $15.9 million for the third quarter of 2025. R&D expenses for the first nine months of 2026 were $57.0 million, compared to $45.2 million for the first nine months of 2025. The $11.8 million year-over-year increase for the first nine months resulted primarily from an $8.9 million increase in clinical trial expense, reflecting increased alisertib study activity, and an increase of approximately $2.9 million in internal R&D expense, primarily due to increased employee compensation including the hiring of a new executive.

Total Other Income (Expenses)

Total other income was $0.9 million for the third quarter of 2026, compared to total other expenses of $0.4 million for the third quarter of 2025. Total other income was $2.0 million for the first nine months of 2026, compared to total other expenses of $1.5 million for the first nine months of 2025. The $3.5 million year-over-year increase in other income for the first nine months of 2026 resulted primarily from a decrease in interest expense, reflecting a lower debt balance, as Puma paid down its debt principal in May 2026, partially offset by the termination of subleases as of March 31, 2026 and unfavorable exchange rates on Euro-denominated transactions.

Fourth Quarter and Full Year 2026 Financial Outlook

Fourth Quarter 2026

New Full Year 2026

Prior Full Year 2026

Net Product Revenue

$56–$58 million

$206–$208 million

$205–$209 million

Royalty Revenue

$11–$12 million

$18–$19 million

$19–$22 million

Total Revenue

$67–$70 million

$224–$227 million

$224–$231 million

Net Income*

$10–$12 million

$20–$22 million

$17–$20 million

Gross to Net Adjustment

28%–29%

27.5%–28%

26.5%–27.5%

Conference Call

Puma Biotechnology will host a conference call to report its third quarter 2026 financial results and provide an update on the Company’s business and outlook at 1:30 p.m. PT/4:30 p.m. ET on Thursday, November 5, 2026. The call may be accessed by dialing (877) 709-8150 (domestic) or (201) 689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at View Source A replay of the call will be available shortly after completion of the call and will be archived on Puma’s website for 90 days.

(Press release, Puma Biotechnology, NOV 5, 2026, View Source [SID1234674340])

Iksuda to Present First Clinical Data for IKS03 in Advanced B-Cell Non-Hodgkin Lymphomas at ASH

On November 5, 2026 Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), reported the presentation of preliminary data from the dose escalation portion of its Phase 1 study of IKS03, a CD19-directed ADC, in patients with advanced B-cell non-Hodgkin lymphoma (B-NHL), at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, December 12–15, 2026, New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of 8 July 2026, 21 patients (median age 67 years) with a median of four prior lines of therapy (range 2-8) have been treated with IKS03 across five dose levels up to 3.1 mg/m2 (approximately 84µg/kg). A maximum tolerated dose (MTD) has not been reached.

IKS03 showed a highly differentiated and manageable safety profile, with treatment-related adverse events (TRAEs) affecting only seven of 21 patients. Compared with other treatments across modalities, there was a markedly lower frequency of high-grade neutropenia and thrombocytopenia and an absence of peripheral neuropathy. A single Grade 4 neutropenia (4.8%), a dose-limiting toxicity, was observed in the fourth dose cohort in a patient with follicular lymphoma and bone marrow involvement, and who had previously received six prior regimens including CAR-T. On resolution, the patient remained on therapy and in response. There were only two Grade 3 neutropenia events, and all remaining TRAEs were mild or moderate (Grade 1–2). No patient experienced a Grade 5 event or a treatment-related serious adverse event, and none stopped treatment because of an adverse event. Non-haematological toxicity was both limited and low-grade.

Responses to treatment were observed from the lowest dose level (around 20 µg/kg) and across all dose cohorts. Of 17 patients evaluable for efficacy (those who had completed two treatment cycles across the first four dose levels), nine responded, giving an overall objective response rate (ORR) of 53%, with two patients achieving stable disease. Five patients (29%) achieved a complete metabolic response: two with follicular lymphoma and one each with diffuse large B-cell lymphoma, marginal zone lymphoma and T cell/histiocyte-rich large B-cell lymphoma. Four patients (24%) achieved a partial metabolic response, two each with follicular lymphoma and marginal zone lymphoma.

Responses were seen in patients who were CAR-T naïve, as well as in those who had received prior CAR-T (3 of 4 patients), including a durable complete response in a patient who had received 8 prior regimens which included failed responses to CAR-T and allogeneic transplantation. Of the eight patients who did not respond, five were being treated for Richter-transformed diffuse large B-cell lymphoma, well known to be highly aggressive and difficult to treat.

Responses have lasted up to 14 months. Currently, six of the nine responders eligible for efficacy assessment at the time of writing remain on treatment. Dose escalation is ongoing and updated results will be presented at the convention.

Dr. Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, commented: "These first clinical data for IKS03 are incredibly exciting. To see responses in patients treated from the lowest dose level and across all cohorts, in heavily pretreated patients including those who had previously received CD19-directed CAR-T therapy, is immensely rewarding, whilst the safety profile is distinct from all other therapies in use for these cancers. These results support the design strategy of tumour-selective payload release, and we look forward to onward progression of this exciting program."

Prof. Enrico Derenzini, European Institute of Oncology IRCCS, Milan, added: "Patients with relapsed or refractory B-cell lymphoma who have already received several lines of treatment have limited options. To see responses at this early stage, alongside a manageable safety profile, is encouraging and supports further evaluation of IKS03."

The Phase 1 study (NCT05365659) is a first-in-human, multicentre trial of IKS03 in patients with relapsed or refractory B-NHL who have received at least two prior systemic therapies. Part I (dose escalation) uses a 3+3 design to determine the MTD and recommended Phase 2 dose in patients with CD19-positive follicular, marginal zone, mantle cell, large B-cell (including Richter-transformed) or high-grade B-cell lymphoma. Part II will assess efficacy in disease-specific expansion cohorts. Around 140 patients are expected to be enrolled across the study.

Presentation details
Abstract number: 5456
Title: First-in-human phase 1 trial to determine safety and preliminary antineoplastic activity of IKS03, a CD19-targeting PBD prodrug antibody drug conjugate, in advanced B-cell non-Hodgkin lymphomas
Presenter: Prof. Enrico Derenzini
Session Name: 629. Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies: Poster III
Session Date: December 14, 2026
Session Time: 12/14/2026 6:00:00 PM – 12/14/2026 8:00:00 PM
Presentation Time: 12/14/2026 6:00:00 PM – 12/14/2026 8:00:00 PM
Room: MCCNO – Hall F

About IKS03

IKS03 is a best-in-class CD19-targeting ADC delivering a tumour-activated prodrug pyrrolobenzodiazepine (PBD) which was licensed from LigaChem Biosciences (formerly LegoChem Biosciences). Preclinical testing demonstrated best-in-class efficacy (vs in-clinic and marketed CD19-targeted therapies) in in vivo xenograft models and significantly raised maximum tolerated dose (MTD) in non-human primate disease models, demonstrating its potential to be the leading anti-CD19 therapy in B-cell cancers.

(Press release, Iksuda Therapeutics, NOV 5, 2026, View Source [SID1234674360])

Alethio Therapeutics Raises $90 Million (£67 Million) in Oversubscribed Series A Financing to Advance a New Generation of Therapies for Myeloproliferative Neoplasms

On November 5, 2026 Alethio Therapeutics ("Alethio"), a biopharmaceutical company developing next-generation therapies for myeloproliferative neoplasms (MPNs), reported the successful completion of an oversubscribed $90 million (£67 million) Series A financing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The substantial round was co-led by new investors Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises, with additional support from Cancer Research Horizons and the University of Oxford. In conjunction with the financing, Graziano Seghezzi, Managing Partner at Sofinnova Partners, and Maxwell DeNies from RA Capital have been appointed to Alethio’s Board of Directors.

The proceeds of the financing will enable Alethio to transition into a clinical-stage company, with capital deployed to advance its lead programme, ATX-011, through completion of Phase 1/2a studies in essential thrombocythaemia (ET), up to Phase 3 readiness, while also progressing additional MPN programmes towards IND submission.

"Too often, a patient’s first encounter with ET is a thrombotic event that lands them in the emergency room," said Dr Rohit Batta, Chief Executive Officer of Alethio Therapeutics. "What follows is typically lifelong treatment with therapies that can cause burdensome side effects and are associated with high rates of resistance. Alethio was founded on a simple conviction – if you can selectively eliminate the cells driving disease, you can redefine what is possible for patients. This financing enables us to turn that conviction into reality."

Founded as a spin-out from the University of Oxford by Professors Adam Mead and Beth Psaila, two of the world’s leading physician-scientists in MPNs, Alethio is building a pipeline of novel therapies informed by their deep expertise in MPN biology. MPNs, including ET, are blood cancers characterised by the uncontrolled production of blood cells and an increased risk of thrombosis, bone marrow scarring (myelofibrosis), and transformation to acute leukaemia.

Current therapies for ET are non-targeted treatments that have been around for decades such as hydroxycarbamide and interferon, that can affect, and disproportionately damage, healthy cells. Alethio is pursuing a different approach, developing targeted therapies designed to selectively eliminate the disease-driving cells that sustain MPNs, to modify the underlying disease features and restore healthy blood counts, reduce thrombotic risk and ultimately improve outcomes for patients.

Preclinical data for ATX-011 has been selected for oral presentation at the American Society of Hematology (ASH) (Free ASH Whitepaper) 2026 Annual Meeting, underscoring the strength of Alethio’s first-in-class G6B-targeting programme. ATX-011 is designed to normalise platelet counts in patients with ET by selectively enhancing platelet clearance through binding G6B, a protein expressed on platelets and megakaryocytes. Importantly, G6B is also aberrantly expressed on MPN-initiating stem cells, but not healthy stem cells, and on megakaryocytes implicated in the development of bone marrow fibrosis. These findings support the potential of ATX-011 to deliver broad therapeutic benefit across patients with MPNs irrespective of driver mutation. Alethio is advancing ATX-011 through IND-enabling studies and toward clinical development in ET.

"The most transformative companies are built around insights that challenge long-held assumptions in medicine," said Graziano Seghezzi, Managing Partner at Sofinnova Partners. "In MPNs, the field has long accepted that controlling the disease is enough. Alethio challenges that assumption. By targeting the cells that drive the disease, its approach has the potential to move patients beyond symptom management toward true disease modification. All of this is based on an exceptional team and founders with a deep understanding of the disease."

"We were drawn to the strength of the biology underpinning Alethio’s approach," said Maxwell DeNies, from RA Capital. "G6B is a highly differentiated target with compelling human data supporting its role in selectively identifying disease-driving cells in MPN. Combined with the extensive patient-derived validation generated by the team, this creates a strong scientific foundation for the programme as it advances toward the clinic."

"Since its formation, Alethio has made incredible progress in translating pioneering University of Oxford science into a focused and ambitious biotechnology company," said Sally Dewhurst, Principal at Oxford Science Enterprises. "The team has built not only a promising lead programme but also the ARTEMIS discovery platform, providing a powerful engine for future pipeline innovation. We are proud to continue supporting the company and are delighted to welcome such an experienced syndicate to help Alethio transition to the next stage of growth; delivering meaningful impact for patients in the clinic."

(Press release, Alethio Therapeutics, NOV 5, 2026, View Source [SID1234674377])

Castle Biosciences Reports Third Quarter 2026 Results

On November 5, 2026 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, reported its financial results for the third quarter and nine months ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our team delivered another strong quarter, reflecting consistent execution across our portfolio," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025. We generated $19.7 million in net cash provided by operating activities, reflecting our disciplined approach to expense management and operational efficiency while continuing to invest in strategic growth opportunities.

"DecisionDx-Melanoma continues to serve as the foundation of our dermatologic testing franchise, with 5% year-over-year growth in test report volume through the first nine months of 2026 compared to the same period in 2025. Alongside DecisionDx-Melanoma, AdvanceAD-Tx and DecisionDx-SCC broaden the clinical value of our dermatologic portfolio and position us to support our medium- and long-term growth opportunities, and combined, our dermatology commercial team delivered 15,168 test reports in the third quarter.

"Overall, our third-quarter results reflect the strength of our portfolio, consistent execution and continued progress toward our long-term growth objectives. I want to thank the entire Castle team for their dedication, hard work and unwavering commitment to improving patient care."

Third Quarter Ended Sep. 30, 2026, Financial and Operational Highlights
•Revenues were $102.9 million, compared to $83.0 million in the third quarter of 2025.

Core revenue drivers:
•Third quarter 2026 total test reports for our core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 22% over the third quarter of 2025:
◦DecisionDx-Melanoma test reports delivered in the quarter were 10,177, compared to 10,459 in the third quarter of 2025.
◦TissueCypher Barrett’s Esophagus test reports delivered in the quarter were 15,574, compared to 10,609 in the third quarter of 2025.

Additional tests:
◦DecisionDx-SCC test reports delivered in the quarter were 3,882, compared to 4,186 in the third quarter of 2025.
◦MyPath Melanoma test reports delivered in the quarter were 798, compared to 1,151 in the third quarter of 2025.

◦DecisionDx-UM test reports delivered in the quarter were 422, compared to 436 in the third quarter of 2025.
◦AdvanceAD-Tx test reports delivered in the quarter were 1,109. The test was not offered during the third quarter of 2025.
◦Esopredict test reports delivered in the quarter were 469. The test was not offered during the third quarter of 2025.

•Gross margin was 75%, and Adjusted Gross Margin was 77%, compared to 75% and 77%, respectively, for the same periods in 2025.
•Net loss, which includes non-cash stock-based compensation expense of $11.2 million, was $4.1 million, compared to net loss of $0.5 million for the same period in 2025.
•Net loss per share and Adjusted Net Loss per Share, Basic and Diluted, was $0.13, compared to net loss per share and Adjusted Net Loss per Share, Basic and Diluted, of $0.02, for the same period in 2025.
•Adjusted EBITDA was $12.7 million, compared to $9.2 million for the same period in 2025.
•Net cash provided by operations was $19.7 million, compared to net cash provided by operations of $22.6 million for the same period in 2025.

Nine Months Ended Sep. 30, 2026, Financial and Operational Highlights
•Revenues were $290.1 million, compared to $257.2 million for the nine months ended September 30, 2025. Affecting comparison to 2025 includes the change in DecisionDx-SCC Medicare coverage effective April 24, 2025, the re-focus of our commercial efforts, as well as the discontinuation of IDgenetix in May 2025.

Core revenue drivers:
•Nine months ended September 30, 2026, total test reports for our core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 29% over the nine months ended September 30, 2025.
◦DecisionDx-Melanoma test reports delivered in the nine months ended September 30, 2026, were 30,478, compared to 29,061 for the same period in 2025.
◦TissueCypher Barrett’s Esophagus test reports delivered in the nine months ended September 30, 2026, were 42,307, compared to 27,211 for the same period in 2025.
Additional tests:
◦DecisionDx-SCC test reports delivered in the nine months ended September 30, 2026, were 11,595, compared to 13,323 for the same period in 2025.
◦MyPath Melanoma test reports delivered in the nine months ended September 30, 2026, were 2,832, compared to 3,243 for the same period in 2025.
◦DecisionDx-UM test reports delivered in the nine months ended September 30, 2026, were 1,396, compared to 1,374 for the same period in 2025.
◦AdvanceAD-Tx test reports delivered in the nine months ended September 30, 2026, were 2,548. The test was not offered during the nine months ended September 30, 2025.
◦Esopredict test reports delivered in the nine months ended September 30, 2026, were 986. The test was not offered during the nine months ended September 30, 2025.

•Gross margin for the nine months ended September 30, 2026, was 74%, and Adjusted Gross Margin was 77%, compared to 67% and 80%, respectively, for the same period in 2025.

•Net loss, which includes non-cash stock-based compensation expense of $32.6 million, was $20.7 million, compared to net loss of $21.8 million for the same period in 2025.
•Net loss per share and Adjusted Net Loss per Share, Basic and Diluted, was $0.69, compared to net loss per share and Adjusted Net Loss per Share, Basic and Diluted, of $0.76 and $0.06, respectively, for the same period in 2025.
•Adjusted EBITDA was $20.0 million, compared to $32.5 million for the same period in 2025.
•Net cash provided by operations was $12.8 million, compared to $37.4 million net cash provided by operations for the same period in 2025.
Cash, Cash Equivalents and Marketable Investment Securities
As of Sep. 30, 2026, the Company’s cash, cash equivalents and marketable investment securities totaled $277.7 million.
2026 Outlook
Castle Biosciences is raising its guidance for anticipated total revenue in 2026. The Company now anticipates generating between $385-395 million in total revenue in 2026, compared to the previously provided guidance of between $365-375 million. Further, the Company maintains its expectation to achieve positive Adjusted EBITDA for the fourth quarter 2026, the full year 2026 and the full year 2027.

Third Quarter 2026 Highlights

Dermatology – Skin Cancer
•In September, the Company presented new data on DecisionDx-Melanoma from the largest, prospective multi-center study of gene expression profiling (GEP) in cutaneous melanoma to date, involving 2,799 patients across 29 U.S. centers. This study, presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026, supports the use of DecisionDx-Melanoma in sentinel lymph node biopsy (SLNB) and risk of recurrence decision-making management. Among 676 patients with low-risk i31-SLNB results who underwent SLNB had an observed SLN positivity of 4.4%, and 565 SLNB-eligible patients with low-risk results who did not undergo SLNB had five-year recurrence-free survival (RFS) of 99.6%. These findings support identifying low-risk patients who may safely forgo SLNB. A separate analysis of 687 patients with transected melanomas showed that patients with early-stage disease (stage I–IIA) and high-risk Class 2B results had recurrence risk similar to stage IIB disease, supporting closer surveillance when staging is uncertain. See the Company’s news release from September 30, 2026, for more information.
•The Company announced the publication of a multi-center study in the Journal of the American Academy of Dermatology (JAAD) validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma (SCC). DecisionDx-SCC analyzes 40 genes to provide results related to prognosis and response to adjuvant radiation therapy (ART) based on an individual patient’s tumor biology. The enhanced algorithm integrates the molecular data with five clinicopathologic risk factors (immunosuppression, tumor diameter, histological differentiation, perineural invasion and anatomic site) using optimized nested predictive models. This integrated approach provides a comprehensive assessment of metastatic risk, local recurrence risk and likelihood of benefit from ART. The study published in JAAD showed that the test results can shift or stratify patients across clinically actionable risk thresholds, supporting risk-aligned decisions regarding patient follow-up, surveillance imaging, multidisciplinary referral and ART. See the Company’s news release from September 9, 2026, for more information.

Dermatology – Atopic Dermatitis
•The Company announced the publication of a new study highlighting the challenges patients with atopic dermatitis (AD) experience in achieving their treatment goals and

strong patient interest in molecular testing to help guide systemic therapy selection. The findings support the clinical need for molecular guidance in AD care. Castle’s AdvanceAD-Tx test is designed to address this need by helping personalize systemic therapy decisions based on an individual patient’s underlying disease biology. This new paper complements an earlier prospective, multicenter clinical validation study in the Journal of the American Academy of Dermatology that demonstrated the ability of AdvanceAD-Tx to identify differences in systemic therapy class response in patients with moderate-to-severe AD. See the Company’s news release from September 24, 2026, for more information.

Gastroenterology
•The Company announced the publication of a study showing that its TissueCypher Barrett’s Esophagus test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett’s esophagus (NDBE). In the study, clinicians changed their management recommendations 90% of the time after receiving TissueCypher results, including escalating management for all patients with intermediate- or high-risk results and de-escalating management for 84% of those with low-risk results. See the Company’s news release from September 28, 2026, for more information.
•The Company announced the publication of a new decision modeling study showing that the TissueCypher Barrett’s Esophagus test can help better align Barrett’s esophagus (BE) management with a patient’s individual risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). In the study, simulated use of TissueCypher significantly increased appropriate management aligned with known progression outcomes across patients with NDBE, indefinite for dysplasia (IND) and low-grade dysplasia (LGD). See the Company’s news release from September 15, 2026, for more information.
Pipeline Initiatives
•In September, SciBase, the Company’s collaboration partner developing the use of electrical impedance spectroscopy technology to predict relapses in atopic dermatitis announced that Castle placed an additional order for acceleration of the Company’s current, ongoing clinical study and preparations for a second clinical study under the collaboration. The order consisted of both the portable pen device and electrodes to a value of approximately $0.6 million. Deliveries began early in the fourth quarter 2026.

Corporate
•The Company announced the opening of its new laboratory and office facility in Scottsdale, Arizona. The 55,000-square-foot facility, located within the 260-acre Perimeter Center business park, expands Castle’s operational footprint in the Phoenix metropolitan area. This investment gives our teams additional space, infrastructure and capacity to support our work on behalf of patients and clinicians today as well as our anticipated growth in the future. See the Company’s news release from September 22, 2026, for more information.

Conference Call and Webcast Details
Castle Biosciences will hold a conference call on Thursday, November 5, 2026, at 4:30 p.m. Eastern time to discuss its third quarter 2026 results and provide a corporate update.

A live webcast of the conference call can be accessed here: View Source or via the webcast link on the Investor Relations page of the Company’s website, View Source Please access the webcast at least 10 minutes before the conference call start time. An archive of the webcast will be available on the Company’s website until November 26, 2026.
There will be a brief Question & Answer session following management commentary.

(Press release, Castle Biosciences, NOV 5, 2026, View Source [SID1234674301])

Medicus Pharma to Present at BIO-Europe 2026

On November 5, 2026 Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, reported that it will be presenting at BIO-Europe 2026, being held on November 9-11, 2026, in Cologne, Germany.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Faisal Mehmud, Chief Medical Officer of Medicus, presentation will highlight the Company’s progress around precision oncology, anchored by CD228V, an investigational antibody-drug conjugate (ADC) molecule utilizing an established vedotin linker-payload platform, as well as SkinJect, an investigational localized immuno-oncology precision product, for multiple basal cell carcinoma lesions in patients with Gorlin syndrome, a rare autosomal dominant genetic disease. The presentation will also cover development and partnership outlook for the Teverelix Program.

Presentation details:

Date: Monday, November 9, 2026
Time: 9:15 to 9:30 a.m. CET
Location: Theatre B, Koelnmesse, Cologne, Germany
Dr. Mehmud will be available to hold one-on-one meetings with institutional investors and prospective partners throughout the conference. The full BIO-Europe 2026 agenda is available on the conference website.

Advancing a Focused Precision Oncology Portfolio

CD228V is an early clinical-stage ADC, utilizing Pfizer’s established vedotin linker-payload platform. Medicus is prioritizing clinical proof-of-concept in melanoma, particularly relapsed, refractory or immunotherapy-resistant disease, with biomarker research intended to guide further development. The Company believes that evidence generated in melanoma could support evaluation in additional CD228-expressing solid tumors.

Medicus aims to build clinical evidence in defined patient populations while pursuing partnerships that can contribute expertise and development resources.

(Press release, Medicus Pharma, NOV 5, 2026, View Source [SID1234674317])